Anticipating HCP Prescribing Behavior Pre-Diagnosis: PulsePoint’s Approach to Rare Disease Omnichannel Marketing Efficiency
In rare disease marketing, timing is one of the most crucial components of a prescriber choosing your treatment. Traditional claims-based targeting often activates 30 days after diagnosis, when treatment decisions are already in motion. PulsePoint helped a pharmaceutical brand move messaging earlier in the clinical journey by identifying high-probability prescribers before patient diagnosis, when treatment considerations were actively forming.
Using a predictive, multi-signal targeting framework, PulsePoint combined real-time digital engagement, clinical procedure patterns, and brand interactions to continuously identify and engage HCPs during narrow, high-impact windows. The approach was powered by PulsePoint’s connected omnichannel ecosystem and core product offerings: HCP Explorer, HCP365, and Life.
The results speak for themselves:
- HCP engagement window expanded by 35-60+ days pre-diagnosis
- 5-8x concentrated media spend on the right HCPs for increased efficiencies
- More net-new prescribers
The results validate that greater impact comes from reaching fewer physicians at the right moment, not broader, untimed coverage.
See how you can replicate the results.
Get the case study →
